Evidence map›Paper›PMID 41797347›Full record

ArticleInfection & chemotherapy2026

Safety and Effectiveness of Biktarvy

Shin-Woo Kim, Jami Peters, Markus G Lang, Jeong-A Lee, Jinhye Cha, Yeon-Sook Kim

Abstract read
In one paragraph

Article in Infection & chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shin-Woo KimDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.ORCID https://orcid.org/0000-0002-3755-8249
Jami PetersGilead Sciences, Inc., Foster City, CA, USA.ORCID https://orcid.org/0009-0000-5430-0955
Markus G LangGilead Sciences, Inc., Foster City, CA, USA.ORCID https://orcid.org/0009-0001-0220-7473
Jeong-A LeeGilead Sciences Korea, Seoul, Korea.ORCID https://orcid.org/0000-0001-7953-2357
Jinhye ChaGilead Sciences Korea, Seoul, Korea.ORCID https://orcid.org/0009-0004-0940-4500
Yeon-Sook KimDivision of Infectious Diseases, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea. alice@cnuh.co.kr.ORCID https://orcid.org/0000-0003-1142-5488

Funding

Gilead Sciences Korea Ltd.
6 · The paper itself

Abstract

We present the results of the 4

Indexed as

BictegravirEmtricitabineKoreaPostmarketing product surveillanceTenofovir alafenamide

Identifiers

PMID41797347
PMCPMC13053886

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.